Solazyme Inc (NASDAQ:SZYM)
| 12.60 Real-Time Quote |  +0.56 / +4.65%Today’s Change | 6.45 Today|||52-Week Range 14.34 | +60.31% Year-to-Date |
Latest SZYM News | Press Releases
| Commit To Purchase Solazyme At $10, Earn 35% Annualized Jun 14 / TheStreet.com | Alternative Jet Fuels Taking Off Jun 06 / MotleyFool.com |
| 3 Opportunities for Solazyme Investors Jun 12 / MotleyFool.com |
Today’s Trading
| Previous close | 12.04 |
| Today’s open | 12.10 |
| Day’s range | 12.00 - 12.65 |
| Volume | 628,431 |
| Average volume (3 months) | 593,405 |
| Market cap | $744.4M |
| Dividend yield | -- |
Data as of 12:49pm ET, 06/19/2013
Growth & Valuation
| Earnings growth (last year) | -1.48% |
| Earnings growth (this year) | -13.55% |
| Earnings growth (next 5 years) | +35.00% |
| Revenue growth (last year) | +13.20% |
| P/E ratio | NM |
| Price/Sales | 10.78 |
| Price/Book | 4.01 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MNTAMomenta Pharmaceutic... | +0.02 | +0.14% |
| HALOHalozyme Therapeutic... | +0.05 | +0.86% |
| ITMNInterMune Inc | +0.17 | +1.73% |
| PLXProtalix Biotherapeu... | +0.10 | +1.97% |
Data as of 12:51pm ET, 06/19/2013
Financials
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.40 |
| Annual revenue (last year) | $44.1M |
| Annual profit (last year) | -$83.1M |
| Net profit margin | -188.47% |
Profile
Sector Process Industries |
Industry Chemicals: Specialty |
President & Director Harrison F. Dillon, PhD |
Chief Executive Officer & Director Jonathan S. Wolfson, MBA |
Corporate headquarters San Francisco, California |
Forecasts
